Vulvovaginal candidiasis and susceptibility of pathogens to antifungal agents;Vulvovaginálna kandidóza a citlivost' patogénov na antimykotiká

Ceska Gynekologie

Volumn 68, Issue 1, 2003, Pages 24-29

  Sojáková, Monika ^a   Liptajova D ^b   Simoncicova M ^c   Borovsky M ^a   Subik J ^b  

^a I Gynekol Porod Klin LFUK a FN   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c Lekárska Fakulta UK ^*  (Slovakia)

Author keywords

Antifungal agents; In vitro resistance; Vulvovaginal candidiasis

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; PATHOGENESIS; TREATMENT OUTCOME; TREATMENT PLANNING; VAGINA CANDIDIASIS; YEAST;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 0345269904     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bernhardt, H., Zimmermann, K., Knoke, M.: Fungal resistance. Infect., 27(S2), 1999, s. 52-54.
2. Bossche, H. V., Dromer, F., Improvisi, I. et al.: Antifungal drug resistance in pathogenic fungi. Med. Mycol., 36(S1), 1998, s. 119-128.
3. Eckert, L. O., Hawes, S. E., Stevens, C. E. et al.: Vulvovaginal candidiasis: Clinical manifestations, Risk factors, Management Algorithm. Obstet. Gynecol., 92, 1998, s. 757-765.
4. Fav-Havard, P., Capano, D., Smith, S. M. et al.: Development of resistance in Candida isolates from patients receiving antifungal therapy. Antimicrob. Agents Chemother., 34, 1991, s. 2302-2305.
5. Koehler, A. P., Chu, K. Ch., Houang, E. T. S. et al.: Simple, reliable, an cost effective yeast identification scheme for the clinical laboratory. J. Clin. Microbiol., 37, 1999, 2, s. 422-426.
6. Kliment, M., Korbeš, M., Hrúzik, P. et al.: Etiológia, patogenéza a diagnostika akútnej a recidivujúcej vulvovaginálnej kandidózy. Prakt. Gynek., 5, 1998, s. 1-7.
7. Lynch, M. E., Sobel, J. D.: Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J. Med. Vet. Mycol., 32, 1994, s. 267-274.
8. National Committee For Clinical Laboratory Standards (NCCLS) Publication M27-A: Reference Method For Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. Wayne, PA: NCCLS, 17, 1997, 9, s. 1-28.
9. Nižňanská, Z.: Výskyt patogénov sexuálne prenosných ochorení u detí a adolescentiek. Doktorandská dizertačná práca, Bratislava, Univerzita Komenského, Lekárska fakulta, 2001, s. 111.
10. Nyirjesy, P., Seeney, S. M., Gody, M. H. T. et al.: Chronic fungal vaginitis: The value of cultures. Am. J. Obstet. Gynecol., 173, 1995, s. 820-823.
11. O'Connor, M. I., Sobel, J. D.: Epidemiology of recurrent vulvovaginal candidiasis: Identification and strain differentiation of Candida albicans. J. Infect. Dis., 88, 1986, s. 596-600.
12. Odds, F. C.: Resistance of yeasts to azole-derivate antifungals. J. Antimicrob. Chemother., 31, 1993, s. 463-471.
13. Odds, F. C., Bernaerts, R.: CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J. Clin. Microbiol., 32, 1994, 8, s. 1923-1929.
14. Paugam, A., Benchtrit, M., Fiacre, A. et al.: Comparison of four commercialized biochemical systems for clinical yeast identification by colour-producing reactions. Med. Mycol., 37, 1999, s. 11-17.
15. Redecha, M., Korbeš, M., Kliment, M. et al.: Súčasné možnosti liečby vulvovaginálnej kandidózy. Prakt. Gynek., 5, 1998, s. 8-13.
16. Sanglard, D., Ischer, F., Calabrese, D. et al.: Multiple resistance mechanism to azole antifungals in yeast clinical isolates. Drug Resistance Updates, 1, 1998, s. 155-265.
17. Sobel, J. D., Faro, S., Force, R. W. et al.: Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol., 178, 1998, 2, s. 203-211.
18. Sobel, J. D.: Limitation of antifungal agents in the treatment of candida vaginitis: future challenges. Drug Resistance Updates, 2, 1999, s. 148-152.
19. Spinillo, A., Capuzzo, E., Egbe, T. O. et al.: Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am. J. Obstet. Gynecol., 176, 1997, s. 138-141.
20. Spinillo, A., Capuzzo, E., Nicola, S. et al.: The impact of oral contraception on vulvovaginal candidiasis. Contraception, 51, 1995, s. 193-297.
21. Takada, M., Kubota, T., Hogaki, M.: Attributes of microorganisms that contribute to recurrence and intractability of vaginal mycosis. Acta Obstet. Jpn., 38, 1986, s. 1125-1134.
22. White, C. T., Maar, K. A., Bowden, R. A.: Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev., 11, 1998, 2, s. 382-402.